BMI1 and neoplasm: We demonstrate that both PTC 209 treatment and stable transfection with a Bmi1-specific shRNA plasmid decrease Bmi1 mRNA and protein expression in the mammary CSCs and inhibit proliferation in vitro and tumor growth in vivo at relatively lower doses after orthotopic implantation into syngeneic fully immunocompetent host.